SIM P. DIMITROFF, M.D.; GEORGE C. GRIFFITH, M.D.; M. C. THORNER, M.D.; JOSEPH WALKER, M.D.
This content is PDF only. Please click on the PDF icon to access.
The cardiac glycoside, gitalin, was first isolated from Digitalis purpurea by Kraft 40 years ago.1 It has been used extensively in Europe, where some investigators believed it to be superior to other digitalis glycosides.2, 3 Studies reported from American clinics during 1934-1938 expressed only limited enthusiasm for its merits,4, 5, 6 and it was not accepted as standard therapy.
Interest in the drug has recently been re-awakened by the introduction of an amorphous form of gitalin which was stable and uniform,7 and which was found to equal other glycosides in its ability to induce adequate initial and maintenance digitalization.8 In
DIMITROFF SP, GRIFFITH GC, THORNER MC, et al. CLINICAL EVALUATION OF GITALIN IN THE TREATMENT OF CONGESTIVE HEART FAILURE*. Ann Intern Med. 1953;39:1189–1199. doi: https://doi.org/10.7326/0003-4819-39-6-1189
Download citation file:
Published: Ann Intern Med. 1953;39(6):1189-1199.
Cardiology, Heart Failure.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use